Fox Chase Cancer Center News

PHILADELPHIA (March 30, 2020)—A group of Fox Chase Cancer Center clinicians featured their expertise in an article that advised physicians on the best approach to take with patients who have been diagnosed or are currently under treatment for cancer during the ongoing COVID-19 pandemic.

PHILADELPHIA (March 27, 2020) —  A retrospective study of lesions classified as clustered microcysts between 2005 and 2015 found no malignancies in any of the 196 lesions.

PHILADELPHIA (March 26, 2020)— When there is an absence of BRCA1, excessive RNF168 expression may drive break-induced replication and contribute to mutational characteristics seen in BRCA1-mutated cancers.

PHILADELPHIA (March 25, 2020)—A study by researchers at Fox Chase Cancer Center published today found that the RNF168 signaling pathway is critical for preventing the growth of BRCA1 mutant cancers, and that new drugs, designed to restore this pathway, could be effective for treating cancers with BRCA1 gene mutations.

PHILADELPHIA (March 19, 2020) – Researchers at the Fox Chase Cancer Center have clarified a fundamental host defense mechanism that detects the presence of influenza virus and rapidly destroys infected cells. “Influenza virus Z-RNAs induce ZBP1-mediated necroptosis” was published in Cell.

PHILADELPHIA (March 17, 2020) — A study led by a researcher at Fox Chase Cancer Center concluded that a combination of body mass index (BMI) and levels of albumin can predict how well older adults with cancer will be able to tolerate the side effects of chemotherapy.

PHILADELPHIA (March 13, 2020)—Fox Chase Cancer Center researchers have published a study suggesting that genomic profiles measured through circulating free DNA (cfDNA) in the blood of breast cancer patients may provide a more effective way to treat cancer and track its progression.

PHILADELPHIA (March 10, 2020) — A 10-year update of a randomized, prospective study conducted by researchers at Fox Chase Cancer Center has found that conventional fractionated and moderate hypofractionated radiation therapy for localized prostate cancer were equally effective.